Doctor Leslie Marisol Lugo Gavidia

Doctor Leslie Marisol Lugo Gavidia

CONSAM, Santiago de Queretaro (Mexico)

Member of:

Dr. Leslie Marisol Lugo Gavidia, MD, MSc. Graduate of Queretaro ́s Autonomous University; Mexico 2014 and certified as a medical doctor (M.D.) she continued her training on cardiovascular disease in the Queretaro´s Heart Institute (Mexico) and participated in national projects focusing on projects to improve coronary artery disease diagnosis, treatment and prognosis. She obtained her Master´s degree in biomedical sciences (2017) on which she focused platelet aggregation and CAD. Following this, she did a fellowship in Barcelona at the Bellvitge Biomedical Research Institute (IDIBELL) in the Bellvitge University Hospital focused on antithrombotic therapy and CAD and the impact to the long term outcome on this patients. Currently PhD student at The University of Western Australia in the Medical Research Foundation (MRF), Royal Perth Hospital (RPH) and Dobney Hypertension Centre (DHC).

Presentations

Impact of the type of acute coronary syndrome on the pharmocodynamic response to P2Y12 inhibitors in the acute and maintenance phase of therapy

Event: ESC Congress 2019

Topic: Thrombosis, Platelets, and Coagulation

Session: New insights for acute coronary syndrome pharmacotherapy

Access

Impact of 2017 ACC/AHA new recommendation for blood pressure target goals on an hispanic population

Event: ESC Congress 2018

Topic: Epidemiology, Prognosis, Outcome

Session: Environmental and global impacts on blood pressure

Access

Underuse of prasugrel and ticagrelor in patients with chronic kidney disease despite achieving a more effective platelet inhibition than clopidogrel

Event: ESC Congress 2017

Topic: Thrombosis and platelets

Session: Acute coronary syndromes

Access

Impact of insulin therapy on thienopyridine- and ticagrelor- mediated platelet inhibition in patients with an acute coronary syndrome

Event: ESC Congress 2017

Topic: Thrombosis and platelets

Session: Acute coronary syndromes

Access

Doctor Leslie Marisol Lugo Gavidia

Biography

Contributor content

Impact of the type of acute coronary syndrome on the pharmocodynamic response to P2Y12 inhibitors in the acute and maintenance phase of therapy

Impact of 2017 ACC/AHA new recommendation for blood pressure target goals on an hispanic population

Underuse of prasugrel and ticagrelor in patients with chronic kidney disease despite achieving a more effective platelet inhibition than clopidogrel

Impact of insulin therapy on thienopyridine- and ticagrelor- mediated platelet inhibition in patients with an acute coronary syndrome

ESC 365 is supported by